



## Dr Enrique Sendagorta Appointed Managing Director of PharmaMar

**Madrid 18 January 2007:** PharmaMar is today pleased to announce the appointment of Dr Enrique Sendagorta as the Company's new Managing Director. Currently based in Madrid as Vice President of Bristol-Myers Squibb's operations in Spain, he will take up his appointment on 12 February.

Dr Sendagorta, 48, has over 20 years' international experience in the pharmaceutical industry. After qualifying as a Doctor of Medicine at the University of Madrid in 1987, he spent twelve years at Hoffman-La Roche, undertaking a number of research, product promotion and senior management roles in Switzerland, France and the United States.

He joined GM Searle, a subsidiary of Monsanto, in 1999 to run Searle's Spanish operations and then moved to Lisbon in 2000, following the merger between Pharmacia and Searle, where he managed Pharmacia's business in Portugal. He was appointed Vice President, Operations of Bristol Myers Squibb in Spain in 2002 with responsibility for all commercial operations in Spain. BMS is the sixth largest manufacturer of pharmaceuticals in Spain with sales of Euros 553 million in 2005 and 503 employees.

Dr Sendagorta, who qualified as a Master of Business Administration at the Stern School of Business, New York University in 1997, is the author of 30 scientific publications. He is also currently a non-executive director of an engineering and systems integration consultancy, Sener Ingeniería y Sistemas, S.A.

Commenting on his appointment, Dr Jose Maria Fernandez, Chairman of Zeltia, the parent company of PharmaMar, said:

"We are very pleased that Dr Sendagorta has agreed to become the new Managing Director of PharmaMar. He has a wealth of experience in the pharmaceutical industry in a variety of senior management roles and joins PharmaMar at an important time in its development, with the company's lead cancer product, Yondelis, currently submitted for approval in Europe. His experience and leadership capabilities will be of great value to PharmaMar as it moves forward and we are delighted to welcome him to the company."

### About PharmaMar

PharmaMar is the world's leading biopharmaceutical company in advancing cancer care through the discovery and development of innovative, marine-derived medicines. PharmaMar's clinical portfolio currently includes 5 compounds: Yondelis<sup>®</sup> (co-developed with J&JPRD), in Phase III clinical trials, was designated Orphan Drug status for soft tissue sarcomas and ovarian cancer by the European Commission (E.C.) and by the United States Food and Drug Administration (US FDA); Aplidin<sup>®</sup>, in Phase II, was designated Orphan Drug status for acute lymphoblastic leukaemia and multiple

myeloma by the E.C. and the US FDA; Kahalalide F, in Phase II; Zalypsis® and PM02734, in Phase I clinical trials.

PharmaMar, based in Madrid, Spain, is a subsidiary of the Zeltia Group (Spanish stock exchange, ZEL).

---

For more information, contact:

**Media:**

David Yates

Financial Dynamics

Tel: +44 20 7831 3113

**Investors:**

Catherine Moukheibir

Zeltia Capital Markets Operations

Tel: +34 91 444 4500

This press release is also available in the News section on PharmaMar's web site:  
<http://www.pharmamar.com/en/press/>